🧬 Regulatory B cells (Bregs) are emerging as key regulators of immune homeostasis and disease. A timely review on their biology and therapeutic potential. 📖 vist.ly/5dp74 #Immunology #Immunotherapy #BCells

Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting

Abstract. The field of immunology is increasingly intersecting with molecular biology, metabolic biology, and neurobiology (Zhu et al, A neuroimmune circui

doi.org

PI3K hyperactivation is a key driver of APDS and related immune disorders. This review explores disease mechanisms, diagnostic strategies, targeted treatments, and remaining clinical challenges. vist.ly/5d68s #IEI #Immunology #PrecisionMedicine

Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives

Abstract. The phosphoinositide-3-kinase (PI3K) pathway function is crucial to the normal development, differentiation, and function of immune cells includi

doi.org

Regulatory B cells (Bregs) help maintain immune tolerance, but their roles in autoimmune disease are remarkably diverse. This review explores how Breg phenotypes and functions vary across conditions and what that means for future therapies. 🔗 vist.ly/5d4vc

Heterogeneity of regulatory B cells in autoimmune diseases: implications for immune equilibrium and therapeutic strategies

Abstract. Regulatory B cells (Bregs) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. However, in autoimmune conditi

doi.org

Radiolabeled nanobodies are emerging as powerful tools for cancer imaging, offering rapid target detection and high target-to-background contrast. Explore their growing role in supporting cancer diagnosis and immunotherapy monitoring. 🔗 vist.ly/5cyc9 #CancerResearch

🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it. Read: vist.ly/5cvmh

🧬 New research suggests G-CSF supportive care may come with an immunological trade-off: improved neutrophil recovery but reduced checkpoint blockade efficacy in immunotherapy-responsive pancreatic cancer models. vist.ly/5cr86 #PancreaticCancer #Immunotherapy #Oncology #CancerResearch

Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer

AbstractIntroduction. Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treat

doi.org

🔬 Radiolabeled nanobodies are emerging as powerful tools for cancer immunotherapy, enabling non-invasive imaging of tumours, immune checkpoints, and immune cells to support patient selection and treatment monitoring. 📖 vist.ly/5c72w

🧬 CAR-T cells and TCR-T cells don't regulate cytokine production in the same way. Patel and colleagues show that while co-stimulatory receptors are needed to sustain late cytokine production in TCR-T cells, this regulation is largely lost in 2nd-generation CAR-T cells. 📖 vist.ly/5c3w8

🎗️ Cancer stem cells may be a key missing piece in understanding immunotherapy resistance. This comprehensive review examines how CSCs interact with the tumour microenvironment and discusses emerging strategies to target stemness-driven therapeutic failure. 📖 vist.ly/5btf3

🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors. Read the open access article: vist.ly/5bip5 #Immunotherapy #CellTherapy

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄vist.ly/5ba67

NLRC5 is more than an MHC-I regulator. Shukla et al. show that tumour-intrinsic NLRC5 promotes CD8⁺ T-cell and NK-cell infiltration, rewires antigen-processing pathways, and drives tumour control, highlighting its potential as a target to enhance antitumour immunity. 🧬 vist.ly/5b6jx

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy. This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening. 📄 vist.ly/5asfu

🔬 New pediatric PID data: fSCIG 10% maintained stable IgG levels across ages 2–16 years, with comparable PK profiles and support for individualized dosing. A step toward reducing treatment burden while preserving effective IgG replacement. 💉 vist.ly/5agfe

Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease

AbstractIntroduction. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is a unique and effective treatment for primary immunodeficienc

doi.org

A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs. Read the open access article: vist.ly/5adn2

Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction. Read the study: vist.ly/59xtz

CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy. 🔗 vist.ly/59urf

A new study protocol describes a controlled human lung immune challenge using inhaled Resiquimod (R848) to investigate antiviral immune responses and airway inflammation, helping to advance respiratory research and novel therapy development. 🔗 vist.ly/59qts

🔬 A high-affinity ImmTAC® can redirect T cells to kill PRAME+ tumour cells, even at low antigen levels. A promising approach for targeting hard-to-reach cancer antigens. 📖 vist.ly/59jfd

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME

AbstractBackground. PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an

doi.org

PRAME-targeted ImmTAC® efficiently redirected T cells to kill tumour cells, with activity enhanced by anti-PD-1 therapy, highlighting its potential across multiple cancer types. 📖 vist.ly/595zb #Immunotherapy #Oncology #CancerResearch

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME

AbstractBackground. PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an

doi.org

🔬 MAGE-A4-specific TCR-NK cells showed potent preclinical activity against solid tumors, combining targeted and innate tumor killing in a promising off-the-shelf cell therapy. 🔗 vist.ly/593g8

Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors

Abstract. T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for ta

doi.org

M2 macrophages may help protect against asthma by promoting IL-10⁺ regulatory B cells. In a mouse model, macrophage depletion worsened asthma symptoms, while findings suggest M2 macrophages support IL-10⁺ B-cell activity via TGF-β and oxidative phosphorylation pathways. 📖 vist.ly/58wxa

M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice

AbstractIntroduction. B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact

doi.org

🔬 M2 macrophages can boost IL-10–producing B cells, helping reduce inflammation and ease asthma symptoms in mouse models. Highlights a potential new avenue for modulating immune responses in asthma. 📖 vist.ly/58v4w #Immunology #Asthma

M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice

AbstractIntroduction. B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact

doi.org

📍 We're at #OCION2026 today in Oxford! Stop by the Immunotherapy Advances booth to meet our Journals Manager, Laura Franklin, and chat about publishing your latest immunology and immuno-oncology research. We're actively welcoming submissions! 🧬✨

Discover the benefits available when peer reviewing for the @britsocimm.bsky.social journals, including a chance to work with immunology experts to advance research. 🔗 oxford.ly/4fWq6kZ #ImmunoSky | @ceijournal.bsky.social | @imtadvances.bsky.social | @discovimmunol.bsky.social

🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/588k5 #Immunology #MultipleSclerosis

🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/587dc #Immunology #MultipleSclerosis

CAR-T cells lose the temporal regulation of cytokine production seen in TCR-T cells, producing sustained high cytokine levels without external co-stimulation, which may underpin both their potency and toxicity. 🔬 vist.ly/584c5 #Immunology

Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells

Abstract. CD8+ T cells contribute to immune responses by producing cytokines when their T-cell receptors (TCRs) recognise peptide antigens on major-histoco

doi.org

Phase 3 data show 20% subcutaneous Ig (Ig20Gly) given weekly or every 2 weeks maintains protective IgG levels (>8 g/L) with a favourable safety profile in Japanese patients with PIDs. Flexible dosing with promising clinical impact. vist.ly/57csr #Immunology

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study

Abstract. This phase 3, open-label, multidose study (NCT04346108) evaluated the pharmacokinetics, safety, tolerability, and efficacy of immunoglobulin subc

doi.org

Study shows comparable cellular immunogenicity in chronic plaque psoriasis patients receiving continuous Humira® or repeated switching with biosimilar AVT02, supporting interchangeability findings. vist.ly/57a58 #Psoriasis #Biosimilars #Immunology

Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02

Summary. Immunogenicity against biologic medicines is ubiquitous, and it is traditionally measured by the final humoral response. However, the onset of a s

doi.org